Cargando…

Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies

Various advances have been made in the treatment of retinal diseases, including new treatment strategies and innovations in surgical devices. However, the treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age‐related macular degeneration (AMD), continues to pose a sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Uyama, Hirofumi, Mandai, Michiko, Takahashi, Masayo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986097/
https://www.ncbi.nlm.nih.gov/pubmed/33315237
http://dx.doi.org/10.1111/dgd.12704
_version_ 1783668374545367040
author Uyama, Hirofumi
Mandai, Michiko
Takahashi, Masayo
author_facet Uyama, Hirofumi
Mandai, Michiko
Takahashi, Masayo
author_sort Uyama, Hirofumi
collection PubMed
description Various advances have been made in the treatment of retinal diseases, including new treatment strategies and innovations in surgical devices. However, the treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age‐related macular degeneration (AMD), continues to pose a significant challenge. In this review, we focus on the use of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to treat retinal diseases by harnessing the ability of stem cells to differentiate into different body tissues. The retina is a tissue specialized for light sensing, and its degradation leads to vision loss. As part of the central nervous system, the retina has very low regenerative capability, and therefore, treatment options are limited once it degenerates. Nevertheless, innovations in methods to induce the generation of retinal cells and tissues from ESCs/iPSCs enable the development of novel approaches for these irreversible diseases. Here we review some historical background and current clinical trials involving the use of stem‐cell‐derived retinal pigment epithelial cells for AMD treatment and stem cell‐derived retinal cells/tissues for RP therapy. Finally, we discuss our future vision of regenerative treatment for retinal diseases with a partial focus on our studies and introduce other interesting approaches for restoring vision.
format Online
Article
Text
id pubmed-7986097
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79860972021-03-25 Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies Uyama, Hirofumi Mandai, Michiko Takahashi, Masayo Dev Growth Differ Review Articles Various advances have been made in the treatment of retinal diseases, including new treatment strategies and innovations in surgical devices. However, the treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age‐related macular degeneration (AMD), continues to pose a significant challenge. In this review, we focus on the use of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to treat retinal diseases by harnessing the ability of stem cells to differentiate into different body tissues. The retina is a tissue specialized for light sensing, and its degradation leads to vision loss. As part of the central nervous system, the retina has very low regenerative capability, and therefore, treatment options are limited once it degenerates. Nevertheless, innovations in methods to induce the generation of retinal cells and tissues from ESCs/iPSCs enable the development of novel approaches for these irreversible diseases. Here we review some historical background and current clinical trials involving the use of stem‐cell‐derived retinal pigment epithelial cells for AMD treatment and stem cell‐derived retinal cells/tissues for RP therapy. Finally, we discuss our future vision of regenerative treatment for retinal diseases with a partial focus on our studies and introduce other interesting approaches for restoring vision. John Wiley and Sons Inc. 2021-01-21 2021-01 /pmc/articles/PMC7986097/ /pubmed/33315237 http://dx.doi.org/10.1111/dgd.12704 Text en © 2020 The Authors. Development, Growth & Differentiation published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Developmental Biologists This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Uyama, Hirofumi
Mandai, Michiko
Takahashi, Masayo
Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title_full Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title_fullStr Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title_full_unstemmed Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title_short Stem‐cell‐based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies
title_sort stem‐cell‐based therapies for retinal degenerative diseases: current challenges in the establishment of new treatment strategies
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986097/
https://www.ncbi.nlm.nih.gov/pubmed/33315237
http://dx.doi.org/10.1111/dgd.12704
work_keys_str_mv AT uyamahirofumi stemcellbasedtherapiesforretinaldegenerativediseasescurrentchallengesintheestablishmentofnewtreatmentstrategies
AT mandaimichiko stemcellbasedtherapiesforretinaldegenerativediseasescurrentchallengesintheestablishmentofnewtreatmentstrategies
AT takahashimasayo stemcellbasedtherapiesforretinaldegenerativediseasescurrentchallengesintheestablishmentofnewtreatmentstrategies